Executive Director, Companion Diagnostics & Clinical Biomarkers

Tango Therapeutics•Boston, MA

7d•$1 - $1

About The Position

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Tango’s labs and offices are located at 201 Brookline Avenue, in the vibrant Fenway area of Boston, Massachusetts. We are seeking an Executive Director, Companion Diagnostics & Clinical Biomarkers to own the strategy and execution of companion diagnostics (CDx) and all clinical biomarker efforts across our oncology portfolio. This individual will be accountable for delivering the global deployment of companion diagnostics (IHC and NGS-based) in alignment with pivotal clinical studies and the overall clinical development plan. The role is highly cross-functional, with responsibility for driving CDx programs from early development through approval, internationally, in close partnership with internal and external stakeholders. Additionally, responsibility includes development and deployment of all other clinical biomarker efforts.

Requirements

PhD or equivalent qualification and 15+ years of experience in biotechnology/pharmaceutical industry
Significant experience in precision oncology and companion diagnostics including driving and executing regulatory strategy
Demonstrated track record of owning and delivering CDx programs
Deep understanding of CDx co-development with therapeutics
Direct experience supporting or leading a CDx program through domestic & international regulatory approval (e.g., FDA PMA, CE mark, PMDA)
Experience with both IHC and NGS-based diagnostics
Proven ability to lead and manage external diagnostic partnerships
Operator with a track record of delivering complex, cross-functional programs
Strong ownership mindset with accountability for, decisions, timelines, budgets and outcomes
Experienced in navigating drug–diagnostic co-development challenges
Effective at driving alignment across internal teams and external partners
Focused on practical execution and results

Responsibilities

CDx Strategy & Program Ownership
Own CDx strategy and execution across all relevant programs
Drive delivery of IHC- and NGS-based CDx to support pivotal studies and approvals
Partner closely with Program Management to ensure alignment between therapeutic development timelines and CDx readiness
Identify risks early and drive mitigation to avoid delays in clinical or regulatory timelines
Clinical & Regulatory Integration
Ensure effective integration of biomarkers into clinical trials to support eventual CDx claims, including:
Patient selection strategies
Operational execution across global study sites
Partner closely with Regulatory Affairs to define and support CDx regulatory submission plans
Ensure CDx development activities are aligned with requirements for approval and labeling
Contribute CDx expertise to regulatory interactions and documentation
External Partner Leadership
Lead selection, negotiation, and management oversight of diagnostic partners and vendors
Serve as the primary point of accountability for all external clinical biomarker collaborations
Drive performance, timelines, and deliverables across partners
Cross-Functional Execution
Partner closely with Clinical Development, Clinical Operations, Medical Affairs, Translational Sciences, Data Management, Program Management, Quality & Compliance, and Regulatory Affairs.
Ensure CDx strategy is endorsed by leadership and embedded in clinical development plans and key decision-making forums
Drive alignment across functions to support efficient program execution
Ensure biomarker efforts are focused on clinical utility and CDx enablement